We investigated the influence of concomitant tuberculosis treatment on the plasma clearance of EFV
Efavirenz (EFV) and rifampicin–isoniazid (RH) are cornerstone drugs in human immunodeficiency virus (HIV)–tuberculosis (TB) coinfection treatment but with
Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial -
Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis
Efavirenz concentrations were higher on than off tuberculosis treatment (2700 versus 2450 ng/mL, P < 0
The geometric mean ratio (GMR) for trough dolutegravir concentrations on
Plasma efavirenz concentration and CYP2B6*6, CYP3A5*3, *6 and *7, ABCB1 3435C Study population
Eur J Clin Pharmacol 2011; 68:689-695
Antiretroviral therapy reduces mortality in patients co-infected with HIV and tuberculosis and should be started during the first 8 weeks of tuberculosis treatment, irrespective of the patient's CD4 cell count
There are several treatment regimens recommended in the United States for TB disease
Methods: Participants receiving daily rifapentine and isoniazid with efavirenz had pharmacokinetic evaluations at baseline and weeks 2 and 4 of
EFV pharmacokinetic exposure is significantly increased by several genetic polymorphisms in CYP2B6 [ 5 – 9 ]
We monitored efavirenz levels in all tuberculosis-HIV-treated patients over 2 years
Methods: HIV-infected patients with active tuberculosis, receiving rifampicin > 1 month, were randomized to receive
The mobile phase consisted of 0
India has the world’s highest burden of Tuberculosis and the third largest number of people living with HIV in the world; it also ranks third in the world for
On the basis of the tolerability and efficacy of raltegravir 400 mg twice This study aims to determine the safety of higher doses of rifampicin and its effect on the pharmacokinetics of efavirenz (EFV) and dolutegravir (DTG) in TB-HIV co-infected patients
The proportion of patients starting ART while receiving concurrent tuberculosis therapy increased from 21% (17 of 80) in 2001 to 40% (439 of 1099) in 2006